Get the Stockscreener App
2.82
0.00%
0.02
Enveric Biosciences Inc stock is traded at $2.82, with a volume of 877.47K.
It is up +0.00% in the last 24 hours and up +54.70% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
See More
Previous Close:
$2.80
Open:
$2.42
24h Volume:
877.47K
Relative Volume:
0.35
Market Cap:
$5.15M
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-0.4393
EPS:
-6.42
Net Cash Flow:
$-11.56M
1W Performance:
+104.38%
1M Performance:
+54.70%
6M Performance:
-63.41%
1Y Performance:
-88.76%
1-Day Range:
$2.40
$2.92
1-Week Range:
$1.13
$4.50
52-Week Range:
$1.13
$28.05
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Compare ENVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
2.82 | 5.15M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.19 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.55 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.98 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.96 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.86 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Discusses Acquisition of Exclusive License from Diverse Biotech and Value Catalysts Moving Forward in New Video Interview on SNN Network - ACCESS Newswire
Best Small Cap Stocks To Follow NowFebruary 26th - MarketBeat
Top Biotech Stocks To Watch TodayFebruary 26th - MarketBeat
Enveric CEO says company is ‘at the forefront’ of neuroplastogens field - TipRanks
Enveric Biosciences advances novel neuroplastogen EB-003 By Investing.com - Investing.com Canada
Can Enveric's Non-Hallucinogenic Psychedelic Drug Transform Mental Health Treatment? - StockTitan
This Biotech Soared On Key Announcement - The Globe and Mail
Biotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent News - Investorideas.com newswire
Dow Dips Over 100 Points; TJX Earnings Top Views - Benzinga
Stock market news: Enveric Biosciences +105.51%, Porch Group +65.96% among top gainers during midday trading - Business Upturn
Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum - openPR
Stock market today: Enveric Biosciences +126.69%, AtlasClear Holdings +52.88% among top gainers in early trading - Business Upturn
Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn
Enveric Biosciences Prepares Presentation for February 2025 - TipRanks
Enveric Biosciences (ENVB) Stock Gains Momentum In Pre-Hour Trading - Stocks Telegraph
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga India
Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds - Microdose Psychedelic Insights
EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD - Benzinga
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent - The Bakersfield Californian
Can Enveric's Newly Patented Compounds Transform Addiction and ADHD Treatment? Patent Details Revealed - StockTitan
ENVB stock touches 52-week low at $1.47 amid market shifts - Investing.com Nigeria
Psychedelic: Exclusive talk with biotech company Enveric Biosciences - TipRanks
ENVB stock touches 52-week low at $1.47 amid market shifts By Investing.com - Investing.com South Africa
Market Movers: Reborn Coffee, Nxu, and Perfect Moment Surge While Enveric Biosciences Plunges - HPBL
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
ENVB stock touches 52-week low at $1.51 amid market challenges - MSN
Enveric Biosciences unit in licensing pacts with Restoration Biologics - TipRanks
Looking For A Good Stock? Let This Enveric Biosciences Inc (NASDAQ: ENVB) Analysis Help. - Stocks Register
Is Enveric Biosciences Inc (ENVB) worth investing in despite its undervalued state? - US Post News
Enveric Biosciences and Restoration Biologics signs licensing agreements to treat joint disease - MSN
A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements - Microdose Psychedelic Insights
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease - Marketscreener.com
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease - Benzinga India
Major Biotech Licensing Deal: Enveric's $82M Agreement Targets Revolutionary Arthritis Therapy - StockTitan
Enveric Biosciences Announces Closing of $5 Million Public Offering - Lelezard
Enveric Biosciences Announces Closing Of $5 Million Public Offering -February 03, 2025 at 05:37 pm EST - Marketscreener.com
Biotech Capital Raise: Enveric Secures Fresh $5M Funding Through Strategic Share Offering - StockTitan
Stock summary: Enveric Biosciences declined by 55.78% over the past five days amid $5 million public offerings made by the company - Business Upturn
Enveric Biosciences Prices of $5 Million Public Offering - citybiz
Enveric Biosciences Down Sharply After Public Offering - MarketWatch
Stock market news: Enveric Biosciences -44.59%, Benson Hill -40.15% among biggest losers during mid day trading - Business Upturn
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
Enveric Biosciences Prices $5 Million Public Offering; Shares Dr - GuruFocus.com
Stock market today: Enveric Biosciences -47.18%, Benson Hill -42.53% among biggest losers in early trading - Business Upturn
Stock market today: Perfect Moment posted rise of 89.86% whereas Enveric Biosciences saw fall of 45.64% in early trading - Business Upturn
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading - Yahoo Finance
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):